ImmuPharma PLC presses on with next phase of Lupuzor clinical trials

ImmuPharma PLC (AIM:IMM, OTC:IMMPF) is set to initiate a Phase 2/3 adaptive clinical trial for its P140 (Lupuzor) drug in systemic lupus erythematosus...

Related Keywords

Tim Mccarthy ,Drug Administration ,Avion Pharmaceuticals ,Art Deas ,